From biology to patient benefit.
CAPItello-281 brings PTEN-targeted therapy closer to clinical reality. Proud to contribute to this research.
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @Annals_Oncology @tompowles1
623 views · 15 likes · 9 reposts · 1 reply
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.org📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281. 🔗https://shorturl.at/c6tvw @Daniel_J_George在 X 查看被引用的帖子
- Michiel Strijbos@StrijbosMichiel
@DrYukselUrun @myESMO @OncoAlert @OpenMedicineHQ @Annals_Oncology @tompowles1 Absolutely groundbreaking! 🌟 CAPItello-281 is a true testament to the power of translating cutting-edge biology into life-changing patient outcomes. Your vital contribution is inspiring—here’s to more transformative milestones that redefine precision medicine! 👏🔬
Source: Yüksel Ürün · x.com